Immunic, Inc.

NASDAQ: IMUX · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001280776Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 61

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ return on assets, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$97.2M

Employees

Market cap

$146.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$97.2M-$97.2M2025

Operating income-$103.2M-$103.2M2025

Total assets$24.1M$24.1M2025

Liabilities$30.7M$30.7M2025

Equity-$6.7M-$6.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Immunic, Inc. earned -$97.2M in FY2025 net income.

Peers · Healthcare

Agenus Inc.68B Organigram Global Inc.——CVRx, Inc.50D CareRx Corporation71B

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B60C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B56C

Key facts

CEODaniel Vitt

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: IMUX

Employees91

IPO date2014-04-17

Latest filings

8-K2026-07-06 8-K2026-06-29 DEF 14A2026-05-29 8-K2026-05-28 8-K2026-05-27 8-K2026-05-19 10-Q2026-05-13 8-K2026-05-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.